Medigene Immunotherapies GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative immunotherapies for the treatment of cancer. The company focuses on harnessing the power of the immune system to create targeted therapies that can effectively combat various forms of cancer. Medigene's research encompasses T-cell receptor (TCR) therapies and dendritic cell vaccines, aiming to enhance patient outcomes through personalized medicine approaches. The organization is committed to advancing its technologies to address unmet medical needs in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

12 Patents

#7 in Planegg

#3,300 in Germany

#48,209 in the World

Planegg, Germany

Medigene Immunotherapies Gmbh

Forward Citations = 9

18 inventors:

Carina Wehner (7 out of 7 patents)

Slavoljub Milosevic (6 out of 7 patents)

Christian Ellinger (6 out of 9 patents)

4. Dolores Schendel (5 out of 21 patents)

5. Manon Weis (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medigene Immunotherapies Gmbh. Retrieved from https://idiyas.com/company/medigene-immunotherapies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

9 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]